New anticoagulants: Moving on from scientific results to clinical implementation

被引：3

作者：

Eerenberg, Elise S. ^{[1
]}

van Es, Josien ^{[1
]}

Sijpkens, Meertien K. ^{[1
]}

Buller, Harry R. ^{[1
]}

Kamphuisen, Pieter W. ^{[1
]}

机构：

[1] Univ Amsterdam, Acad Med Ctr, Dept Vasc Med, NL-1105 AZ Amsterdam, Netherlands

来源：

ANNALS OF MEDICINE | 2011年 / 43卷 / 08期

关键词：

Anticoagulants; antidote; clinical trials; factor Xa; monitoring; thrombin; thrombosis; DIRECT THROMBIN INHIBITOR; ORAL DIRECT THROMBIN; FACTOR-XA INHIBITOR; TOTAL HIP-REPLACEMENT; DABIGATRAN ETEXILATE; VENOUS THROMBOEMBOLISM; KNEE ARTHROPLASTY; DOUBLE-BLIND; ACTIVE PRODRUG; RIVAROXABAN;

D O I：

10.3109/07853890.2011.606829

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Vitamin K antagonists (VKA) are the only registered oral anticoagulants for the treatment of venous thromboembolism (VTE). VKA have an unpredictable and highly variable effect on coagulation, with a high risk of under- and over-treatment. Novel anticoagulants, such as dabigatran and rivaroxaban, could be a very welcome replacement for VKA, as they show a predictable anticoagulant effect. Results of several phase II and III studies have shown the efficacy and safety of dabigatran and rivaroxaban in the prophylaxis and treatment of VTE, and for the prevention of stroke in atrial fibrillation. It remains to be shown whether these new anticoagulants have the same safety profile in daily clinical practice, where more vulnerable patients will be treated. Lack of information on the proper monitoring method or antidote in case of bleeding may also hinder the translation from science to clinical practice.

引用

页码：606 / 616

页数：11

共 63 条

[11] Rivaroxaban versus enoxaparin for thromboprophylaxis after total hip or knee arthroplasty: a meta-analysis of randomized controlled trials [J].

Cao, Yong Bing ;

Zhang, Jun Dong ;

Shen, Hui ;

Jiang, Yuan Ying .

EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2010, 66 (11) :1099-1108

[12]

Castellone DD, 2007, J THROMB HAEMOST S2, V5

[13] Dabigatran versus Warfarin in Patients with Atrial Fibrillation. [J].

Connolly, Stuart J. ;

Ezekowitz, Michael D. ;

Yusuf, Salim ;

Eikelboom, John ;

Oldgren, Jonas ;

Parekh, Amit ;

Pogue, Janice ;

Reilly, Paul A. ;

Themeles, Ellison ;

Varrone, Jeanne ;

Wang, Susan ;

Alings, Marco ;

Xavier, Denis ;

Zhu, Jun ;

Diaz, Rafael ;

Lewis, Basil S. ;

Darius, Harald ;

Diener, Hans-Christoph ;

Joyner, Campbell D. ;

Wallentin, Lars .

NEW ENGLAND JOURNAL OF MEDICINE, 2009, 361 (12) :1139-1151

[14] Managing bleeding in anticoagulated patients with a focus on novel therapeutic agents [J].

Crowther, M. A. ;

Warkentin, T. E. .

JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2009, 7 :107-110

[15] Update on Antithrombotic Therapy New Anticoagulants [J].

Eikelboom, John W. ;

Weitz, Jeffrey I. .

CIRCULATION, 2010, 121 (13) :1523-1532

[16] Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement:: the RE-MODEL randomized trial [J].

Eriksson, B. I. ;

Dahl, O. E. ;

Rosencher, N. ;

Kurth, A. A. ;

Van Dijk, N. ;

Frostick, S. P. ;

Kalebo, P. ;

Christiansen, A. V. ;

Hantel, S. ;

Hettiarachchi, R. ;

Schnee, J. ;

Buller, H. R. .

JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2007, 5 (11) :2178-2185

[17] Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty [J].

Eriksson, Bengt I. ;

Borris, Lars C. ;

Friedman, Richard J. ;

Haas, Sylvia ;

Huisman, Menno V. ;

Kakkar, Ajay K. ;

Bandel, Tiemo J. ;

Beckmann, Horst ;

Muehlhofer, Eva ;

Misselwitz, Frank ;

Geerts, William .

NEW ENGLAND JOURNAL OF MEDICINE, 2008, 358 (26) :2765-2775

[18] Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement:: a randomised, double-blind, non-inferiority trial [J].

Eriksson, Bengt I. ;

Dahl, Ola E. ;

Rosencher, Nadia ;

Kurth, Andreas A. ;

van Dijk, C. Niek ;

Frostick, Simon P. ;

Prins, Martin H. ;

Hettiarachchi, Rohan ;

Hantel, Stefan ;

Schnee, Janet ;

Bueller, Harry R. .

LANCET, 2007, 370 (9591) :949-956

[19] Comparative Pharmacodynamics and Pharmacokinetics of Oral Direct Thrombin and Factor Xa Inhibitors in Development [J].

Eriksson, Bengt I. ;

Quinla, Datfiel J. ;

Weitz, Jeffrey I. .

CLINICAL PHARMACOKINETICS, 2009, 48 (01) :1-22

[20] A new oral direct thrombin inhibitor, dabigatran etexilate, compared with enoxaparin for prevention of thromboembolic events following total hip or knee replacement:: the BISTRO II randomized trial [J].

Eriksson, BI ;

Dahl, OE ;

Büller, HR ;

Hettiarachchi, R ;

Rosencher, N ;

Bravo, ML ;

Ahnfelt, L ;

Piovella, F ;

Stangier, J ;

Kälebo, P ;

Reilly, P .

JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2005, 3 (01) :103-111

← 1 2 3 4 5 6 7 →